Zhengye Biotechnology Holding Ltd (ZYBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Zhengye Biotechnology Holding Ltd (ZYBT) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.77

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Zhengye Biotechnology Holding Ltd (ZYBT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Zhengye Biotechnology Holding Ltd (ZYBT) has a current Price-to-Book (P/B) ratio of 1.25. Compared to its 3-year average P/B ratio of 6.29, the current P/B ratio is approximately -80.07% higher. Relative to its 5-year average P/B ratio of 6.29, the current P/B ratio is about -80.07% higher. Zhengye Biotechnology Holding Ltd (ZYBT) has a Forward Free Cash Flow (FCF) yield of approximately 0.08%. Compared to its 3-year average FCF yield of 1.76%, the current FCF yield is approximately -95.35% lower. Relative to its 5-year average FCF yield of 1.76%, the current FCF yield is about -95.35% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ZYBT competitors is 1.07, providing a benchmark for relative valuation. Zhengye Biotechnology Holding Ltd Corp (ZYBT.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ZYBT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ZYBT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ZYBT currently overvalued or undervalued?

What is Zhengye Biotechnology Holding Ltd (ZYBT) fair value?

ZYBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Zhengye Biotechnology Holding Ltd (ZYBT) is between to according to relative valuation method.

How does ZYBT's valuation metrics compare to the industry average?

The average P/S ratio for ZYBT's competitors is 1.07, providing a benchmark for relative valuation. Zhengye Biotechnology Holding Ltd Corp (ZYBT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Zhengye Biotechnology Holding Ltd (ZYBT) as of Mar 03 2026?

As of Mar 03 2026, Zhengye Biotechnology Holding Ltd (ZYBT) has a P/B ratio of 1.25. This indicates that the market values ZYBT at 1.25 times its book value.

What is the current FCF Yield for Zhengye Biotechnology Holding Ltd (ZYBT) as of Mar 03 2026?

As of Mar 03 2026, Zhengye Biotechnology Holding Ltd (ZYBT) has a FCF Yield of 0.08%. This means that for every dollar of Zhengye Biotechnology Holding Ltd's market capitalization, the company generates 0.08 cents in free cash flow.

What is the current Forward P/E ratio for Zhengye Biotechnology Holding Ltd (ZYBT) as of Mar 03 2026?

As of Mar 03 2026, Zhengye Biotechnology Holding Ltd (ZYBT) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Zhengye Biotechnology Holding Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Zhengye Biotechnology Holding Ltd (ZYBT) as of Mar 03 2026?

As of Mar 03 2026, Zhengye Biotechnology Holding Ltd (ZYBT) has a Forward P/S ratio of 0.00. This means the market is valuing ZYBT at $0.00 for every dollar of expected revenue over the next 12 months.

ZYBT Valuation